source
- FDA advisory panel backs Replimune’s melanoma immunotherapy combined with OpdivoThe FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10-3 to recommend Replimune’s RP1 immunotherapy, used together with Bristol Myers Squibb’s Opdivo, for patients with advanced…
- Trump administration delays start of first pharma tariff wave originally set for July 31President Donald Trump's administration had scheduled the first set of pharmaceutical tariffs to begin on July 31, but the rollout has been postponed. A White House official said the implementation…